In this work we have provided evidence that the Ser/Thr kinase CK1α is a pivotal regulator of the BCR cascades and may be targeted to enhance the cytotoxic effects of BCR inhibitors, suggesting the rationale for innovative therapeutic strategies for patients with MCL in association with novel agents. The gene discussed is CSNK1A1; the disease is mantle cell lymphoma.